Literature DB >> 37878

Elimination of nadolol by patients with renal impairment.

J Herrera, R A Vukovich, D L Griffith.   

Abstract

1 Nadolol excretion was studied in 24 patients with chronic renal failure. 2 The amount of nadolol excreted during the 120-h period after receiving the drug ranged from less than 1% in functionally anephric, patients up to 11.5% in patients with average creatinine clearance of 57.9 +/- 3.6 ml/min/1.73 m2. 3 Renal clearance of nadolol was found to correlate with creatinine clearance; nadolol elimination is retarded in patients with renal failure. 4 Nadolol serum half-life is prolonged in proportion to the remaining renal function. Therefore, dosage intervals in renal patients receiving nadolol should be adjusted to creatinine clearance. 5 Haemodialysis effectively reduced serum concentration of the drug; it may therefore be a useful therapy for drug intoxication.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 37878      PMCID: PMC1429334          DOI: 10.1111/j.1365-2125.1979.tb04694.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  10 in total

1.  Fluorometric determination of nadolol in human serum and urine.

Authors:  E Ivashkiv
Journal:  J Pharm Sci       Date:  1977-08       Impact factor: 3.534

2.  Pharmacokinetics and hepatic extraction ratio of pindolol in hypertensive patients with normal and impaired renal function.

Authors:  D Lavene; Y A Weiss; M E Safar; Y Loria; N Agorus; D Georges; P L Milliez
Journal:  J Clin Pharmacol       Date:  1977 Aug-Sep       Impact factor: 3.126

3.  Pharmacology of nadolol (SQ 11725), a beta-adrenergic antagonist lacking direct myocardial depression.

Authors:  R J Lee; D B Evans; S H Baky; R J Laffan
Journal:  Eur J Pharmacol       Date:  1975 Sep-Oct       Impact factor: 4.432

4.  Elimination of furosemide in healthy subjects and in those with renal failure.

Authors:  B Beermann; E Dalén; B Lindström
Journal:  Clin Pharmacol Ther       Date:  1977-07       Impact factor: 6.875

5.  Comparison of the new beta-adrenoceptor antagonist, nadolol, and propranolol in the treatment of angina pectoris.

Authors:  B Furberg; A Dahlqvist; A Raak; U Wrege
Journal:  Curr Med Res Opin       Date:  1978       Impact factor: 2.580

6.  Dose-ranging study of the new beta-adrenergic antagonist nadolol in the treatment of essential hypertension.

Authors:  G Frithz
Journal:  Curr Med Res Opin       Date:  1978       Impact factor: 2.580

7.  Drug dosage in patients with impaired renal function.

Authors:  L Dettli; P Spring; R Habersang
Journal:  Postgrad Med J       Date:  1970-10       Impact factor: 2.401

8.  Studies on the epidemiology of adverse drug reactions. V. Clinical factors influencing susceptibility.

Authors:  J W Smith; L G Seidl; L E Cluff
Journal:  Ann Intern Med       Date:  1966-10       Impact factor: 25.391

9.  Pharmacokinetics and hemodialyzability of cefazolin in uremic patients.

Authors:  C P Craig; S I Rifkin
Journal:  Clin Pharmacol Ther       Date:  1976-06       Impact factor: 6.875

10.  Metabolic studies in patients with nadolol: oral and intravenous administration.

Authors:  J Dreyfuss; L J Brannick; R A Vukovich; J M Shaw; D A Willard
Journal:  J Clin Pharmacol       Date:  1977 May-Jun       Impact factor: 3.126

  10 in total
  8 in total

1.  Bioequivalence of a highly variable drug: an experience with nadolol.

Authors:  R G Buice; V S Subramanian; K L Duchin; S Uko-Nne
Journal:  Pharm Res       Date:  1996-07       Impact factor: 4.200

Review 2.  The new beta-adrenergic antagonists.

Authors:  D C Chung; M J Laschuk
Journal:  Can Anaesth Soc J       Date:  1984-07

Review 3.  Clinical pharmacokinetics of beta-adrenoceptor antagonists. An update.

Authors:  J G Riddell; D W Harron; R G Shanks
Journal:  Clin Pharmacokinet       Date:  1987-05       Impact factor: 6.447

Review 4.  Antihypertensive therapy in the aged patient. Clinical pharmacokinetic considerations.

Authors:  R W Piepho; K J Fendler
Journal:  Drugs Aging       Date:  1991-05       Impact factor: 3.923

Review 5.  Cardiovascular drug therapy in the elderly: theoretical and practical considerations.

Authors:  Bradley R Williams; Jiwon Kim
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

6.  Differences in kinetic properties of drugs: implications as to the selection of a particular drug for use in patients with renal failure with special emphasis on antibiotics and beta-adrenoceptor blocking agents.

Authors:  J Fabre; H M Fox; P Dayer; L Balant
Journal:  Clin Pharmacokinet       Date:  1980 Sep-Oct       Impact factor: 6.447

Review 7.  Nadolol: a review of its pharmacological properties and therapeutic efficacy in hypertension and angina pectoris.

Authors:  R C Heel; R N Brogden; G E Pakes; T M Speight; G S Avery
Journal:  Drugs       Date:  1980-07       Impact factor: 9.546

8.  Extracorporeal treatment for poisoning to beta-adrenergic antagonists: systematic review and recommendations from the EXTRIP workgroup.

Authors:  Josée Bouchard; Greene Shepherd; Robert S Hoffman; Sophie Gosselin; Darren M Roberts; Yi Li; Thomas D Nolin; Valéry Lavergne; Marc Ghannoum
Journal:  Crit Care       Date:  2021-06-10       Impact factor: 9.097

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.